.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,048,439

« Back to Dashboard

Details for Patent: 8,048,439

Title:Therapeutic foam
Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurized canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimizing the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.
Inventor(s): Wright; David Dakin Iorwerth (Buckinghamshire, GB), Harman; Anthony David (Oxfordshire, GB), Robinson; Nikki (Uxbridge, GB), Hodges; Garry (Middlesex, GB), Kadar; Adil (Middlesex, GB), Moggridge; Geoffrey D. (Cambridge, GB), Van Liew; Hugh (Barnstable, MA), Jenkins; William John (London, GB)
Assignee: BTG International Ltd. (London, GB)
Filing Date:May 13, 2005
Application Number:11/128,265
Claims:1. A method for angiologic treatment comprising injecting a foam comprising a liquid phase and a gas phase wherein the liquid phase comprises at least one sclerosing agent and the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume, xenon gas in an amount greater than 5% and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen into veins to be treated.

2. The method of claim 1 comprising having a patient breathe oxygen or an oxygen enriched atmosphere prior to injecting the foam.

3. The method for phlebologic treatment comprising injecting a foam comprising a liquid phase and a gas phase wherein the liquid phase comprises at least one sclerosing agent and the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume, xenon gas in an amount greater than 5% and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen into veins to be treated.

4. The method of claim 3 comprising having a patient breathe oxygen or an oxygen enriched atmosphere prior to injecting the foam.

5. The method of claim 4, wherein a greater saphenous vein of one leg of a human patient is treated by a single injection of foam.

6. The method of claim 5, wherein the single injection uses an amount ranging from 10 ml to 50 ml.

7. The method of claim 6, wherein the single injection uses an amount ranging from 10 ml to 40 ml.

8. The method of claim 7, wherein the single injection uses an amount ranging from 15 ml to 30 ml.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc